-
National Healthy Lifestyle Promotion Month | Focusing on Breast Health: Authoritative Experts Discuss Breast Cancer Prevention and Treatment — Part2
Professor Zhimin FanThe First Hospital of Jilin University The global incidence of breast cancer is rising year by year. However, with the implementation of standardized and normalized treatments, mortality rates…
-
The Journal of Hepatology: A New Era Begins at 40
As the Journal of Hepatology marks its 40th anniversary, Vlad Ratziu leads a new editorial team, carrying forward the journal’s legacy of excellence. Over the past two decades, the journal…
-
ASH 2024 | Dr. Minghui Duan: Exploring the Combination of Selinexor and Ruxolitinib in Myelofibrosis Treatment
From December 7 to 10, 2024, the 66th American Society of Hematology (ASH) Annual Meeting took place in San Diego, USA, bringing together global experts to discuss the latest advancements in hematology. During this prestigious event, Dr. Minghui Duan from Peking Union Medical College Hospital presented his team’s latest findings on myelofibrosis (MF) treatment (Abstract…
-
ASH 2024 | Professor Jerald Radich：Mutations and Minimal Residual Disease (MRD): Clinical Implications of Clonal Origins
Minimal residual disease (MRD) is a powerful predictor of relapse in acute myeloid leukemia (AML), yet its accuracy remains a challenge. Some patients who are MRD-positive do not relapse, while others who are MRD-negative still experience disease recurrence. At the 2024 American Society of Hematology (ASH) Annual Meeting, Professor Jerald Radich from Fred Hutchinson Cancer…
-
Case Compilation | The Battle of Outstanding Clinical Cases
Lung cancer remains the most common and deadliest malignancy in China. Optimizing treatment strategies is essential for extending patient survival and improving quality of life. In the era of precision medicine, targeted therapies such as icotinib and befotertinib have provided significant breakthroughs for non-small cell lung cancer (NSCLC), demonstrating the commitment and innovation of Chinese…
-
Updated EASL Guidelines on Hepatocellular Carcinoma Management
Liver cancer is the third leading cause of cancer-related deaths worldwide, with hepatocellular carcinoma (HCC) accounting for nearly 90% of primary liver cancers. The newly updated EASL Clinical Practice Guidelines…
-
ASCO GU 2025 | Dr. Jianming Guo & Dr. Philip Kwong Share Advances in mCRPC Research, Paving the Way for Future Diagnosis and Treatment Strategies
The 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025) is currently taking place in San Francisco, USA. This globally renowned academic conference brings together top oncology experts to explore cutting-edge breakthroughs and future directions in the field of genitourinary cancers. On-site at ASCO GU, Urology Frontier invited Dr. Jianming Guo from…
Connecting Medical Expertise through Media
